Drug Combination Details
| General Information of the Combination (ID: C87491) | |||||
|---|---|---|---|---|---|
| Name | Wogonin NP Info | + | ABT-263 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lymphoma
[ICD-11: 2A80-2A86]
|
Investigative | [1] | ||
|
Chronic lymphocytic leukaemia
[ICD-11: 2A82]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | ARAC-8C | CVCL_GZ09 | T acute lymphoblastic leukemia | Homo sapiens | ||
| MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | |||
| Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | |||
| KM-H2 | CVCL_1330 | Hodgkin lymphoma | Homo sapiens | |||
| In-vivo Model | Immunodeficient mice (Rag2-/-/II2rg-/-) were implanted subcutaneously in the dorsal flank region with CEM (5*107 cells). | |||||
| Experimental
Result(s) |
Wogonin potentiates the lethality of ABT-263 in ABT-263-resistant cancer cells and wogonin reduces the effective dose of ABT-263 thereby possibly decreasing the risk of adverse side effects. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. Int J Cancer. 2015 Feb 1;136(3):688-98. | |||
